Skip to content

Study · Non-randomized trial · n = 10 · 2016

12 results

Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men.

Muskiet MH, Tonneijck L, Smits MM, Kramer MH, Diamant M, Joles JA, van Raalte DH

Diabetes, obesity & metabolism5 Jan 2016Cited by 88 (Europe PMC)

PMID26636423 (opens in a new tab)DOI10.1111/dom.12601 (opens in a new tab)PepBankPUB-26636423
Publisher pagePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanNon-randomized trialMechanism

    In healthy overweight men, exenatide increased GFR by 20% versus placebo.

    In plain wordsIn healthy overweight men, exenatide increased kidney filtration compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseGlomerular filtration rate
    Study

    n = 10

    Comparator
    placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Measurements

    GFR increase
    18
    exenatide versus placebo (SD 20)
    GFR increase
    20%
    exenatide versus placebo

    Source sentences

    Summary
    GFR increased by a mean of 18 ± 20 (+20%; p = 0.021) and ERPF increased by a median (interquartile range) of 68 (26; 197) ml/min/1.73 m(2) (+14%; p = 0.015) during exenatide infusion versus placebo.
    1 context sentence
    Summary · context
    Renal haemodynamics and tubular electrolyte handling were measured in 10 healthy overweight men (aged 20-27 years; BMI 26-31 kg/m(2)) during intravenous administration of placebo (saline 0.9%), exenatide, and exenatide combined with the NO-synthase inhibitor L-N(G)-monomethyl arginine (L-NMMA).
  2. 02HumanNon-randomized trialMechanism

    In healthy overweight men, exenatide increased effective renal plasma flow by 14% versus placebo.

    In plain wordsIn healthy overweight men, exenatide increased kidney plasma flow compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseEffective renal plasma flow
    Study

    n = 10

    Comparator
    placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Measurements

    ERPF increase (median)
    68 ml/min/1.73 m(2)
    exenatide versus placebo (IQR 26 to 197)
    ERPF increase
    14%
    exenatide versus placebo

    Source sentences

    Summary
    GFR increased by a mean of 18 ± 20 (+20%; p = 0.021) and ERPF increased by a median (interquartile range) of 68 (26; 197) ml/min/1.73 m(2) (+14%; p = 0.015) during exenatide infusion versus placebo.
    1 context sentence
    Summary · context
    Renal haemodynamics and tubular electrolyte handling were measured in 10 healthy overweight men (aged 20-27 years; BMI 26-31 kg/m(2)) during intravenous administration of placebo (saline 0.9%), exenatide, and exenatide combined with the NO-synthase inhibitor L-N(G)-monomethyl arginine (L-NMMA).
  3. 03HumanNon-randomized trialMechanism

    In healthy overweight men, exenatide increased estimated glomerular pressure by 6%.

    In plain wordsIn healthy overweight men, exenatide increased estimated glomerular pressure compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseEstimated glomerular pressure
    Study

    n = 10

    Comparator
    placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Measurements

    Estimated glomerular pressure change
    6%
    exenatide vs placebo

    Source sentences

    Summary
    Exenatide increased estimated glomerular pressure by +6% (p = 0.015) and reduced afferent renal vascular resistance by -33% (p = 0.038), whereas these effects were blunted during L-NMMA infusion.
    1 context sentence
    Summary · context
    Renal haemodynamics and tubular electrolyte handling were measured in 10 healthy overweight men (aged 20-27 years; BMI 26-31 kg/m(2)) during intravenous administration of placebo (saline 0.9%), exenatide, and exenatide combined with the NO-synthase inhibitor L-N(G)-monomethyl arginine (L-NMMA).
  4. 04HumanNon-randomized trialMechanism

    In healthy overweight men, exenatide reduced afferent renal vascular resistance by 33%.

    In plain wordsIn healthy overweight men, exenatide reduced afferent kidney vessel resistance compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseAfferent renal vascular resistance
    Study

    n = 10

    Comparator
    placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Measurements

    Afferent renal vascular resistance change
    −33%
    exenatide vs placebo

    Source sentences

    Summary
    Exenatide increased estimated glomerular pressure by +6% (p = 0.015) and reduced afferent renal vascular resistance by -33% (p = 0.038), whereas these effects were blunted during L-NMMA infusion.
    1 context sentence
    Summary · context
    Renal haemodynamics and tubular electrolyte handling were measured in 10 healthy overweight men (aged 20-27 years; BMI 26-31 kg/m(2)) during intravenous administration of placebo (saline 0.9%), exenatide, and exenatide combined with the NO-synthase inhibitor L-N(G)-monomethyl arginine (L-NMMA).
  5. 05HumanNon-randomized trialMechanism

    In healthy overweight men, exenatide increased absolute sodium excretion.

    In plain wordsIn healthy overweight men, exenatide increased absolute sodium excretion compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseAbsolute sodium excretion
    Study

    n = 10

    Comparator
    placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    Exenatide increased absolute and fractional sodium excretion, urinary osmolality and urinary pH.
    1 context sentence
    Summary · context
    Renal haemodynamics and tubular electrolyte handling were measured in 10 healthy overweight men (aged 20-27 years; BMI 26-31 kg/m(2)) during intravenous administration of placebo (saline 0.9%), exenatide, and exenatide combined with the NO-synthase inhibitor L-N(G)-monomethyl arginine (L-NMMA).
  6. 06HumanNon-randomized trialMechanism

    In healthy overweight men, exenatide increased fractional sodium excretion.

    In plain wordsIn healthy overweight men, exenatide increased fractional sodium excretion compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseFractional sodium excretion
    Study

    n = 10

    Comparator
    placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    Exenatide increased absolute and fractional sodium excretion, urinary osmolality and urinary pH.
    1 context sentence
    Summary · context
    Renal haemodynamics and tubular electrolyte handling were measured in 10 healthy overweight men (aged 20-27 years; BMI 26-31 kg/m(2)) during intravenous administration of placebo (saline 0.9%), exenatide, and exenatide combined with the NO-synthase inhibitor L-N(G)-monomethyl arginine (L-NMMA).
  7. 07HumanNon-randomized trialMechanism

    In healthy overweight men, exenatide increased urinary osmolality.

    In plain wordsIn healthy overweight men, exenatide increased urine concentration compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseUrinary osmolality
    Study

    n = 10

    Comparator
    placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    Exenatide increased absolute and fractional sodium excretion, urinary osmolality and urinary pH.
    1 context sentence
    Summary · context
    Renal haemodynamics and tubular electrolyte handling were measured in 10 healthy overweight men (aged 20-27 years; BMI 26-31 kg/m(2)) during intravenous administration of placebo (saline 0.9%), exenatide, and exenatide combined with the NO-synthase inhibitor L-N(G)-monomethyl arginine (L-NMMA).
  8. 08HumanNon-randomized trialMechanism

    In healthy overweight men, exenatide increased urinary pH.

    In plain wordsIn healthy overweight men, exenatide increased urinary pH compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseUrinary pH
    Study

    n = 10

    Comparator
    placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    Exenatide increased absolute and fractional sodium excretion, urinary osmolality and urinary pH.
    1 context sentence
    Summary · context
    Renal haemodynamics and tubular electrolyte handling were measured in 10 healthy overweight men (aged 20-27 years; BMI 26-31 kg/m(2)) during intravenous administration of placebo (saline 0.9%), exenatide, and exenatide combined with the NO-synthase inhibitor L-N(G)-monomethyl arginine (L-NMMA).

Studies that did not test the peptide alone4

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 09HumanNot a test of Exenatide (exendin-4) aloneNon-randomized trialMechanism

    In healthy overweight men, GFR was 9% higher during infusion of exenatide combined with L-NMMA.

    In plain wordsIn healthy overweight men, kidney filtration was higher during a combined exenatide and L-NMMA infusion.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseGFR during L-NMMA infusion
    Study

    n = 10

    Outcome group
    Kidney function · Kidney and urinary

    Measurements

    GFR increase
    8 ml/min/1.73 m(2)
    exenatide during L-NMMA infusion (SD 12)
    GFR increase
    9%
    exenatide during L-NMMA infusion

    Source sentences

    Summary
    During L-NMMA infusion, exenatide increased GFR by mean 8 ± 12 ml/min/1.73 m(2) (+9%; p = 0.049).
    1 context sentence
    Summary · context
    Renal haemodynamics and tubular electrolyte handling were measured in 10 healthy overweight men (aged 20-27 years; BMI 26-31 kg/m(2)) during intravenous administration of placebo (saline 0.9%), exenatide, and exenatide combined with the NO-synthase inhibitor L-N(G)-monomethyl arginine (L-NMMA).

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  2. 10HumanNot a test of Exenatide (exendin-4) aloneNon-randomized trialMechanism

    In healthy overweight men, concomitant L-NMMA blunted the glomerular pressure increase associated with exenatide.

    In plain wordsIn healthy overweight men, adding L-NMMA reduced the glomerular pressure response compared with exenatide alone.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseGlomerular pressure response with L-NMMA
    Study

    n = 10

    Comparator
    exenatide alone
    Outcome group
    Kidney function · Kidney and urinary

    Source sentences

    Summary
    Exenatide increased estimated glomerular pressure by +6% (p = 0.015) and reduced afferent renal vascular resistance by -33% (p = 0.038), whereas these effects were blunted during L-NMMA infusion.
    1 context sentence
    Summary · context
    Renal haemodynamics and tubular electrolyte handling were measured in 10 healthy overweight men (aged 20-27 years; BMI 26-31 kg/m(2)) during intravenous administration of placebo (saline 0.9%), exenatide, and exenatide combined with the NO-synthase inhibitor L-N(G)-monomethyl arginine (L-NMMA).

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  3. 11HumanNot a test of Exenatide (exendin-4) aloneNon-randomized trialMechanism

    In healthy overweight men, concomitant L-NMMA blunted the reduction in afferent renal vascular resistance associated with exenatide.

    In plain wordsIn healthy overweight men, adding L-NMMA weakened the decrease in afferent kidney vessel resistance compared with exenatide alone.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseAfferent resistance response with L-NMMA
    Study

    n = 10

    Comparator
    exenatide alone
    Outcome group
    Kidney function · Kidney and urinary

    Source sentences

    Summary
    Exenatide increased estimated glomerular pressure by +6% (p = 0.015) and reduced afferent renal vascular resistance by -33% (p = 0.038), whereas these effects were blunted during L-NMMA infusion.
    1 context sentence
    Summary · context
    Renal haemodynamics and tubular electrolyte handling were measured in 10 healthy overweight men (aged 20-27 years; BMI 26-31 kg/m(2)) during intravenous administration of placebo (saline 0.9%), exenatide, and exenatide combined with the NO-synthase inhibitor L-N(G)-monomethyl arginine (L-NMMA).

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  4. 12HumanNot a test of Exenatide (exendin-4) aloneNon-randomized trialMechanism

    In healthy overweight men, concomitant L-NMMA did not alter the tubular effects of exenatide.

    In plain wordsIn healthy overweight men, adding L-NMMA did not change tubular responses compared with exenatide alone.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeTubular response during L-NMMA infusion
    Study

    n = 10

    Comparator
    exenatide alone
    Outcome group
    Kidney function · Kidney and urinary

    Source sentences

    Summary
    The tubular effects of exenatide were not altered by concomitant L-NMMA infusion.
    1 context sentence
    Summary · context
    Renal haemodynamics and tubular electrolyte handling were measured in 10 healthy overweight men (aged 20-27 years; BMI 26-31 kg/m(2)) during intravenous administration of placebo (saline 0.9%), exenatide, and exenatide combined with the NO-synthase inhibitor L-N(G)-monomethyl arginine (L-NMMA).

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.